Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 1.00 |
| ▸ | HSD11B2 | P80365 | 8/20 | 0.70 |
| ▸ | TACR3 | P29371 | 3/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2822276 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2TACR3HCRTR1HCRTR2 | |
| SCHEMBL2720258 | 0.90 | HSD11B1 (0.81) | HSD11B1HSD11B2TACR3HCRTR1HCRTR2 | |
| SCHEMBL4995227 | 0.90 | HSD11B1 (0.81) | HSD11B1HSD11B2TACR3HCRTR1HCRTR2 | |
| SCHEMBL2716665 | 0.90 | HSD11B1 (0.81) | HSD11B1HSD11B2TACR3HCRTR1HCRTR2 | |
| SCHEMBL328769 | 0.83 | HSD11B1 (1.00) | HSD11B1HSD11B2TACR3HCRTR1HCRTR2 | |
| SCHEMBL2720948 | 0.81 | HSD11B1 (0.85) | HSD11B1HSD11B2TACR3 | |
| SCHEMBL328846 | 0.81 | HSD11B1 (0.85) | HSD11B1HSD11B2TACR3HCRTR1HCRTR2 | |
| SCHEMBL328946 | 0.79 | HSD11B1 (0.85) | HSD11B1HSD11B2TACR3HCRTR1HCRTR2 | |
| SCHEMBL329009 | 0.79 | HSD11B1 (0.66) | HSD11B1HSD11B2TACR3HCRTR1HCRTR2 | |
| SCHEMBL328965 | 0.79 | HSD11B1 (0.66) | HSD11B1HSD11B2TACR3HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099740-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES | 2015-04-09 | — | — | US | claimed |
| US-20130059829-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBVIE INC. | 2013-03-07 | — | — | US | claimed |
| EP-2407452-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | Abbott Laboratories (US) | 2012-01-18 | — | — | EP | claimed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | claimed |
| WO-2011068927-A2 | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | claimed |
| US-9464072-B2 | Treatment of central nervous system disorders | ABBVIE INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150099740-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES | 2015-04-09 | — | — | US | disclosed |
| US-8940902-B2 | Treatment of central nervous system disorders | ABBVIE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20130059829-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBVIE INC. | 2013-03-07 | — | — | US | disclosed |
| EP-2407452-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | Abbott Laboratories (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099740-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CHAT, HSD17B1, ACHE | HSD11B1 5/4885HSD11B2 14/4885TACR3 3167/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD11B2 3/4885TACR3 4347/4885 |
| US-20130059829-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CHAT, HSD17B1, ACHE | HSD11B1 5/4885HSD11B2 14/4885TACR3 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.